Diffuse Intrinsic Pontine Glioma (DIPG): breakthrough and clinical perspective

Antonio Ruggiero, Maria Grazia Perrone, Antonella Centonze, Antonio Carrieri, Savina Ferorelli, Antonio Scilimati

Risultato della ricerca: Contributo in rivistaArticolo in rivistapeer review

Abstract

Diffuse intrinsic pontine glioma (DIPG) mainly affects children with a median age of 6-7 years old. It accounts for 10% of all pediatric tumors. Unfortunately, DIPG has a poor prognosis, and the median survival is generally less than 16-24 months independently from the treatment received. Up to now, children with DIPG are treated with focal radiotherapy alone or in combination with antitumor agents. In the last decade, ONC201 known as dopamine receptor antagonist was uncovered, by a high throughput screening of public libraries of compounds, to be endowed with cytotoxic activity against several cancer cell lines. Efforts were made to identify the real ONC201 target, responsible for its antiproliferative effect. The hypothesized targets were the Tumor necrosis factor-Related Apoptosis-Inducing Ligand stimulation (TRAIL), two oncogenic kinases (ERK/AKT system) that target the same tumor-suppressor gene (FOXO3a), dopamine receptors (DRD2 and DRD3 subtypes) and finally the mitochondrial Caseynolitic Protease P (ClpP). Carried out ONC201 structure-activity relationship is extensively discussed in this review, together with other two classes of compounds, namely ADEPs and D9, already known for their antibiotic activity but noteworthy to be commented as potential "leads" for the development of new drugs to be used in the treatment of DIPG. In this review, a detailed and critical description of ONC201, ADEPs, and D9 pro-apoptotic activity is made, with particular attention to the specific interactions established with its targets that also are intimately described. Pubmed, published patents and clinical trial reports of the last ten years was the bibliographic source.
Lingua originaleEnglish
pagine (da-a)N/A-N/A
RivistaCURRENT MEDICINAL CHEMISTRY
Volume27
DOI
Stato di pubblicazionePubblicato - 2020

Keywords

  • ADEPs
  • Clinical Trials
  • ClpP
  • D9
  • Diffuse intrinsic pontine glioma (DIPG)
  • ONC201
  • SAR
  • Treatment

Fingerprint

Entra nei temi di ricerca di 'Diffuse Intrinsic Pontine Glioma (DIPG): breakthrough and clinical perspective'. Insieme formano una fingerprint unica.

Cita questo